CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

CSL strikes $1.6B deal with Alentis for experimental kidney, liver drug

Positive
AI Analysis

Summary

CSL Limited announced a $1.6 billion acquisition deal with Alentis Therapeutics to acquire experimental drugs targeting kidney and liver diseases.

Importance:7/10
Sentiment:
0.60
M&Aacquisitionkidney diseaseliver diseasetherapeutic development
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on October 4, 2026 10:41 PM

Read Original